Guillaume Larghero is a dedicated researcher focused on leveraging artificial intelligence (AI) to advance personalized medicine and improve clinical outcomes for life-threatening diseases. Currently an associate at Harvard Medical School in Dr. Kun-Hsing Yu’s lab, Guillaume leads efforts to subtype acute myeloid leukemia (AML) using computer vision, with a focus on predicting key mutational markers and treatment outcomes.
Guillaume earned a Bachelor’s degree in Life Sciences Engineering from EPFL and a Master’s degree in Bioinformatics from ETH Zurich, where he developed a robust foundation in computational biology and machine learning. Following his academic training, he contributed to groundbreaking research at IBM, focusing on the integration of multi-omics datasets to enhance colorectal cancer prediction. His expertise lies at the intersection of computational pathology, machine learning, and bioinformatics, with a primary focus on developing AI-driven tools to address complex challenges in disease diagnosis and therapeutic decision-making.